Semaglutide

Semaglutide
	Semaglutide is the active ingredient in Wegovy injection, Wegovy tablets, and Wegovy HD
Trade names	Wegovy, Wegovy HD, Ozempic, Rybelsus
Generic name	Semaglutide
Drug class	GLP-1 receptor agonist
Routes of administration	Subcutaneous injection; oral tablet
Uses	Chronic weight management, obesity, overweight with weight-related conditions, cardiovascular risk reduction in selected adults, type 2 diabetes under diabetes brands
Indications	Weight loss and long-term maintenance of weight loss; reduction of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight; treatment of noncirrhotic MASH with moderate to advanced liver fibrosis under updated labeling
Mechanism of action	Activates GLP-1 receptors, reduces appetite, increases satiety, slows gastric emptying, improves glucose regulation, and reduces calorie intake
Dosing frequency	Once weekly injection for Wegovy injection and Wegovy HD; once daily tablet for Wegovy tablets
Dosage forms	Prefilled injection pen; oral tablet ;
Contraindications	Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, serious hypersensitivity to semaglutide or excipients
Common side effects	Nausea, vomiting, diarrhea, constipation, abdominal pain, heartburn, headache, fatigue, dizziness
Serious side effects	Pancreatitis, gallbladder disease, dehydration-related kidney injury, allergic reaction, possible thyroid C-cell tumor risk, suicidal ideation warning, hypoglycemia risk when used with insulin or insulin secretagogues ; ;
Related drugs	Wegovy, Wegovy HD, Ozempic, Rybelsus, GLP-1 weight loss, Tirzepatide, Zepbound, Mounjaro, Saxenda, W8MD Weight Loss, Sleep and MedSpa

Successful GLP-1 weight loss requires medical monitoring, nutrition planning, protein intake, side-effect management, and long-term maintenance.

W8MD Weight Loss, Sleep and MedSpa physicians can evaluate patients for Wegovy, Wegovy tablets, Wegovy HD, tirzepatide, traditional weight loss medications, and comprehensive medical weight loss.

W8MD may combine semaglutide treatment with meal replacements, low-carbohydrate diet planning, protein goals, sleep apnea care, and long-term maintenance.

Semaglutide is a prescription GLP-1 receptor agonist used for weight loss, type 2 diabetes, cardiovascular risk reduction in selected patients, and other metabolic indications depending on the brand, dose, and formulation. Wegovy is the semaglutide brand used for chronic weight management. Wegovy is available as a once-weekly injection, a once-daily oral tablet formulation, and a higher-dose once-weekly injection known as Wegovy HD.

Wegovy is used with a reduced-calorie diet and increased physical activity to help eligible patients lose weight and maintain weight loss. It is also approved to reduce the risk of major adverse cardiovascular events such as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke in adults with established cardiovascular disease and either obesity or overweight.FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight(link). U.S. Food and Drug Administration.

Semaglutide works by mimicking the action of glucagon-like peptide-1, also known as GLP-1, a hormone involved in appetite control, satiety, glucose regulation, insulin secretion, glucagon suppression, and gastric emptying. For weight loss, semaglutide helps many patients feel full sooner, stay full longer, reduce hunger, reduce cravings, and consume fewer calories.

W8MD Weight Loss, Sleep and MedSpa Centers can help eligible patients use semaglutide safely and effectively as part of a physician-supervised medical weight loss program. W8MD can evaluate whether Wegovy injection, Wegovy tablets, Wegovy HD, tirzepatide, or another weight-loss medication is appropriate, help with nutrition planning, monitor side effects, support insurance and prior authorization when available, screen for sleep apnea, address insulin resistance, and provide long-term weight maintenance support.

Terminology

Semaglutide is the active ingredient. The brand, dose, formulation, and indication determine how it is used.

Brand or formulation	Active ingredient	Route	Common use
Wegovy injection	Semaglutide	Once-weekly subcutaneous injection	Chronic weight management, cardiovascular risk reduction in selected adults, and other approved metabolic indications
Wegovy tablets	Semaglutide	Once-daily oral tablet	Chronic weight management and cardiovascular risk reduction in eligible adults according to labeling
Wegovy HD	Semaglutide	Once-weekly subcutaneous injection	Higher-dose 7.2 mg option for weight loss and long-term weight maintenance in certain adult patients
Ozempic	Semaglutide	Once-weekly injection	Type 2 diabetes and cardiovascular risk reduction in selected diabetes patients
Rybelsus	Semaglutide	Oral tablet	Type 2 diabetes

Wegovy, Ozempic, and Rybelsus

Wegovy, Ozempic, and Rybelsus all contain semaglutide, but they are not interchangeable without medical guidance.

Product	Main FDA context	Important distinction
Wegovy	Obesity, overweight with weight-related complications, cardiovascular risk reduction in selected adults	Weight-loss brand and dose schedule
Ozempic	Type 2 diabetes	Diabetes brand; often causes weight loss but is not the same label as Wegovy
Rybelsus	Type 2 diabetes	Oral semaglutide diabetes brand
Wegovy tablets	Oral semaglutide under Wegovy labeling	Oral obesity/cardiovascular-risk formulation distinct from Rybelsus dosing

FDA-approved uses of Wegovy

Wegovy is indicated in combination with a reduced-calorie diet and increased physical activity for weight reduction and long-term maintenance of weight reduction in eligible patients. The updated DailyMed label states that Wegovy is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.WEGOVY—semaglutide injection and semaglutide tablets(link). DailyMed, U.S. National Library of Medicine.

Updated labeling also includes Wegovy injection for treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.WEGOVY Prescribing Information(link). U.S. Food and Drug Administration.

Wegovy as an injection

Wegovy injection is administered once weekly under the skin. Traditional Wegovy injection dosing begins at a low dose and gradually increases to reduce gastrointestinal side effects.

Common dose steps include:

0.25 mg once weekly
0.5 mg once weekly
1 mg once weekly
1.7 mg once weekly
2.4 mg once weekly
7.2 mg once weekly as Wegovy HD for selected adult patients

The 2.4 mg once-weekly dose remains the commonly recommended maintenance dose for many adults, while 1.7 mg may be used in selected patients depending on tolerability and indication.WEGOVY Prescribing Information(link). U.S. Food and Drug Administration.

Wegovy as a pill

Wegovy tablets are an oral semaglutide formulation used once daily. This option is important for patients who prefer pills over injections or who have difficulty using injectable medications.

The updated DailyMed label states that the recommended starting dosage of Wegovy tablets is 1.5 mg taken orally once daily, with gradual dose escalation to reduce gastrointestinal adverse reactions. The recommended maintenance dosage is 25 mg orally once daily.WEGOVY—semaglutide injection and semaglutide tablets(link). DailyMed, U.S. National Library of Medicine.

Wegovy tablets may be especially useful for:

Patients who prefer oral medication
Patients with needle anxiety
Patients who travel frequently
Patients who have difficulty storing or using injectable pens
Patients who are appropriate candidates for oral semaglutide under medical supervision

Wegovy tablets still require careful use, dose escalation, side-effect monitoring, and adherence to administration instructions.

Wegovy HD

Wegovy HD refers to the higher-dose 7.2 mg semaglutide injection. The FDA approved a new higher dose of Wegovy injection, called Wegovy HD, on March 19, 2026, for weight loss and long-term maintenance of weight loss in certain adult patients.FDA Approves Fourth Product Under National Priority Voucher Program: Higher Dose Semaglutide(link). U.S. Food and Drug Administration.

Wegovy HD may be considered for selected adults who need additional weight-loss support beyond the standard Wegovy maintenance dose and who tolerate semaglutide therapy. Wegovy’s patient information states that Wegovy HD 7.2 mg may be an option for adults seeking additional weight loss after being on the 2.4 mg dose for at least 4 weeks.FAQs About Wegovy(link). Novo Nordisk.

Why Wegovy HD matters

Some patients respond well to standard-dose semaglutide, while others plateau or do not reach their treatment goals. Higher-dose semaglutide may provide another option for selected adults under medical supervision.

Potential reasons to discuss Wegovy HD include:

Weight-loss plateau on 2.4 mg
High baseline BMI
Need for additional weight reduction
Multiple obesity-related conditions
Good tolerability on lower-dose Wegovy
Need for more intensive nonsurgical medical weight loss

Wegovy HD is not for everyone. Higher doses may increase side-effect risk and require careful medical monitoring.

Cardiovascular benefits

One of the most important advances for Wegovy is its cardiovascular indication. Wegovy is approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight.FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight(link). U.S. Food and Drug Administration.

The SELECT trial studied semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease but without diabetes. The trial showed that semaglutide significantly reduced major adverse cardiovascular events compared with placebo."Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes".New England Journal of Medicine.2023;doi:10.1056/NEJMoa2307563.PMID:37952131.

Potential cardiovascular-related benefits may include:

Reduced risk of cardiovascular death, heart attack, or stroke in eligible adults
Weight reduction
Improved waist circumference
Improved blood pressure in some patients
Improved inflammation markers in some studies
Improved glycemic markers
Improved cardiometabolic risk profile

Wegovy is not a substitute for standard cardiovascular care such as blood pressure control, cholesterol treatment, smoking cessation, antiplatelet therapy when appropriate, exercise, and cardiology follow-up.

Weight-loss benefits

Semaglutide is one of the most effective GLP-1 weight-loss medications. In the STEP 1 clinical trial, adults with overweight or obesity without diabetes treated with once-weekly semaglutide 2.4 mg plus lifestyle intervention lost an average of 14.9% of body weight at 68 weeks compared with 2.4% with placebo."Once-Weekly Semaglutide in Adults with Overweight or Obesity".New England Journal of Medicine.2021;doi:10.1056/NEJMoa2032183.PMID:33567185.

In OASIS 4, oral semaglutide 25 mg once daily produced significantly greater mean body-weight reduction than placebo in adults with overweight or obesity."Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity".New England Journal of Medicine.2025;doi:10.1056/NEJMoa2500969.

Higher-dose semaglutide 7.2 mg was studied in the STEP UP trial. The FDA approval of Wegovy HD was based on higher-dose semaglutide data showing greater weight loss than standard dosing in selected adults.FDA Approves Fourth Product Under National Priority Voucher Program: Higher Dose Semaglutide(link). U.S. Food and Drug Administration.

Benefits beyond weight loss

Although Wegovy is commonly discussed as a weight-loss medication, its benefits may extend beyond the scale in selected patients.

Potential benefits may include:

Reduced appetite
Increased satiety
Reduced cravings
Smaller portions
Weight loss
Long-term weight maintenance
Reduced cardiovascular risk in eligible adults
Improved blood pressure in some patients
Improved triglycerides in some patients
Improved insulin resistance
Reduced risk of progression from prediabetes in some patients
Improved fatty liver risk markers in selected patients
Improved mobility and quality of life
Reduced sleep apnea severity in some patients through weight loss

Wegovy and MASH

Metabolic dysfunction-associated steatohepatitis or MASH is a progressive form of fatty liver disease associated with liver inflammation and fibrosis. Updated Wegovy labeling includes an indication for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.WEGOVY Prescribing Information(link). U.S. Food and Drug Administration.

This is important because obesity, insulin resistance, type 2 diabetes, and fatty liver disease often occur together. Patients with suspected advanced liver disease should be evaluated by appropriate specialists.

Who may qualify for Wegovy?

Wegovy may be considered for selected patients with:

Obesity
Overweight with weight-related medical conditions
Prediabetes
Type 2 diabetes risk
Hypertension
Dyslipidemia
Sleep apnea
Fatty liver disease
MASH
PCOS
Metabolic syndrome
Established cardiovascular disease with obesity or overweight

Eligibility depends on BMI, medical history, medication contraindications, pregnancy status, insurance rules, prior treatment history, side-effect risk, and clinician judgment.

How semaglutide works for weight loss

Semaglutide activates GLP-1 receptors in the brain and body. Its weight-loss effect is mainly related to reduced appetite and increased satiety.

Semaglutide may help by:

Reducing appetite
Increasing fullness
Reducing cravings
Helping patients eat smaller portions
Slowing gastric emptying
Improving blood glucose regulation
Reducing calorie intake
Supporting long-term weight loss when continued

Semaglutide also stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner, helping regulate blood glucose.WEGOVY—semaglutide injection and semaglutide tablets(link). DailyMed, U.S. National Library of Medicine.

Administration

Wegovy injection and Wegovy HD are injected under the skin. Common injection sites include the abdomen, thigh, or upper arm.

Wegovy tablets are taken by mouth once daily according to prescribing instructions. Oral semaglutide absorption can be affected by food, drink, and other medications, so patients should follow their prescriber’s instructions carefully.

Common side effects

Common side effects may include:

Nausea
Vomiting
Diarrhea
Constipation
Abdominal pain
Heartburn
Bloating
Burping
Headache
Fatigue
Dizziness

Side effects are often more noticeable during dose escalation. Strategies such as eating smaller meals, stopping when full, avoiding greasy foods, staying hydrated, using adequate fiber, and slowing dose escalation when medically appropriate may help.

Serious warnings and precautions

Semaglutide should be used only under medical supervision.

Serious risks and precautions include:

Possible thyroid C-cell tumor risk
Medullary thyroid carcinoma contraindication
Multiple endocrine neoplasia syndrome type 2 contraindication
Pancreatitis
Gallbladder disease
Acute kidney injury from dehydration
Serious allergic reactions
Increased heart rate
Suicidal ideation warning
Hypoglycemia risk when used with insulin or insulin secretagogues
Delayed gastric emptying and possible medication absorption issues

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2.WEGOVY—semaglutide injection and semaglutide tablets(link). DailyMed, U.S. National Library of Medicine.

Who should not use Wegovy?

Wegovy may not be appropriate for patients with:

Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia syndrome type 2
Prior serious hypersensitivity to semaglutide
Pregnancy
Planned pregnancy without discontinuation planning
Breastfeeding unless clinician determines benefit and risk
Active pancreatitis
Severe gastrointestinal disease in selected cases
Severe dehydration or inability to maintain fluids

Pregnancy and breastfeeding

Wegovy is not recommended during pregnancy. Patients planning pregnancy should discuss medication discontinuation timing with their healthcare provider. Weight-loss medications are generally not used during pregnancy.

Wegovy and diet

Wegovy helps appetite control, but it does not replace nutrition planning. Patients still need protein, fluids, fiber, vitamins, minerals, and a sustainable eating pattern.

A W8MD-style nutrition plan may emphasize:

Protein at every meal
Low-carbohydrate or low-glycemic meals when appropriate
Non-starchy vegetables
Meal replacements when useful
Adequate hydration
Reduced sugar intake
Reduced refined carbohydrates
Smaller meals
Avoiding overeating despite reduced appetite

Wegovy and protein preservation

Because Wegovy can greatly reduce appetite, some patients may eat too little protein. This can increase the risk of losing muscle mass during weight loss. Protein planning and resistance training are important.

Helpful strategies include:

Protein-first meals
Protein shakes when needed
Resistance training
Strength exercises
Avoiding extreme under-eating
Monitoring fatigue and weakness
Discussing body composition with the care team

Wegovy and exercise

Exercise improves health, preserves muscle, and helps with long-term maintenance. Patients using Wegovy should aim for an individualized exercise plan.

Useful activities include:

Walking
Post-meal walking
Resistance training
Strength training
Cycling
Swimming
Yoga
Daily step goals

Wegovy versus Zepbound

Zepbound contains tirzepatide, not semaglutide. Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide activates GLP-1 receptors. Both medications may be used for chronic weight management in eligible patients, but medication choice depends on medical history, insurance coverage, side effects, contraindications, patient preference, cost, and provider judgment.

Insurance and prior authorization

Insurance coverage for Wegovy varies widely. Some plans cover obesity medications, while others exclude them or require prior authorization. Cardiovascular and MASH indications may affect coverage in selected patients, but coverage rules vary by plan.

W8MD may help patients with:

BMI documentation
Weight-related diagnosis documentation
Cardiovascular history documentation when relevant
Fatty liver or MASH-related documentation when relevant
Medication history
Prior authorization support when available
Alternative medication discussion
Self-pay options when appropriate
Traditional medication options when GLP-1 coverage is limited

How W8MD can help

W8MD Weight Loss, Sleep and MedSpa Centers can help patients use semaglutide safely and effectively as part of comprehensive medical weight loss.

W8MD may help with:

Physician-supervised medical weight loss
Wegovy eligibility evaluation
Wegovy tablet discussion when appropriate
Wegovy HD discussion when appropriate
Semaglutide treatment planning
GLP-1 medication counseling
Dose-escalation support
Side-effect management
Protein and hydration planning
Meal replacements
Low-carbohydrate diet planning
Ketogenic diet guidance when appropriate
Insulin resistance evaluation
Prediabetes screening
Type 2 diabetes risk reduction
PCOS support
Fatty liver disease risk reduction
MASH risk recognition
Metabolic syndrome treatment
Sleep apnea screening
Home sleep test
CPAP support
Traditional medications such as phentermine when appropriate
Long-term weight maintenance

W8MD integrated weight loss and sleep approach

Sleep problems can make weight loss harder. Obstructive sleep apnea can worsen fatigue, hunger, insulin resistance, blood pressure, and weight gain. Because W8MD combines weight loss and sleep medicine, patients using Wegovy can also be evaluated for sleep apnea when symptoms are present.

Sleep apnea symptoms include:

Loud snoring
Witnessed pauses in breathing
Waking up choking or gasping
Morning headaches
Daytime sleepiness
Fatigue
Brain fog
High blood pressure
Weight gain or difficulty losing weight

W8MD affordable weight loss options

Wegovy and other GLP-1 medications may be expensive without insurance. W8MD can help patients consider multiple pathways, depending on medical eligibility and budget.

Options may include:

Insurance-based visits when eligible
GLP-1 medication prior authorization support when available
Wegovy injection options when appropriate
Wegovy tablet options when appropriate
Wegovy HD options when appropriate
Tirzepatide options when appropriate
Traditional medications such as phentermine when appropriate
Meal replacement programs
Low-carbohydrate diet support
800–1200 calorie medical weight-loss plans
Sleep apnea diagnosis and treatment

Why Wegovy is not a magic shot or magic pill

Wegovy can be very effective, but it is not a magic solution. Patients still need to address eating patterns, protein intake, sleep, physical activity, insulin resistance, and maintenance.

Common reasons for poor response include:

Eating beyond fullness
Liquid calories
Low protein intake
Frequent snacking
Poor sleep
Untreated sleep apnea
Medication interactions
Alcohol calories
Stopping follow-up
Not escalating dose when appropriate
Side effects limiting treatment
Not having a maintenance plan

Frequently asked questions

What is semaglutide?

Semaglutide is a GLP-1 receptor agonist medication used in different formulations for weight loss, type 2 diabetes, cardiovascular risk reduction in selected patients, and other metabolic indications.

What is Wegovy?

Wegovy is the semaglutide brand used for chronic weight management. It is available as injection, oral tablet, and higher-dose injection options.

What is Wegovy as a pill?

Wegovy tablets are an oral semaglutide formulation. The recommended maintenance dose in labeling is 25 mg orally once daily.WEGOVY—semaglutide injection and semaglutide tablets(link). DailyMed, U.S. National Library of Medicine.

What is Wegovy HD?

Wegovy HD is the higher-dose 7.2 mg semaglutide injection approved for weight loss and long-term maintenance of weight loss in certain adult patients.FDA Approves Fourth Product Under National Priority Voucher Program: Higher Dose Semaglutide(link). U.S. Food and Drug Administration.

Is Wegovy the same as Ozempic?

No. Wegovy and Ozempic both contain semaglutide, but they have different FDA indications, dosing, labeling, and insurance rules.

Does Wegovy help the heart?

Yes, in selected adults. Wegovy is approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight(link). U.S. Food and Drug Administration.

How much weight can people lose with Wegovy?

In STEP 1, adults using semaglutide 2.4 mg weekly plus lifestyle intervention lost an average of 14.9% of body weight at 68 weeks, compared with 2.4% with placebo."Once-Weekly Semaglutide in Adults with Overweight or Obesity".New England Journal of Medicine.2021;doi:10.1056/NEJMoa2032183.PMID:33567185.

Can W8MD prescribe Wegovy?

W8MD physicians and healthcare providers can evaluate eligible patients for Wegovy, Wegovy tablets, Wegovy HD, or other weight-loss medications when medically appropriate.

Can W8MD help if insurance does not cover Wegovy?

Yes. W8MD can discuss alternative options such as other GLP-1 pathways when available, traditional medications such as phentermine when appropriate, meal replacements, low-carbohydrate plans, and medical weight-loss visits.

Do I still need diet and exercise with Wegovy?

Yes. Wegovy is intended to be used with reduced-calorie diet and increased physical activity.

When to call a doctor

Call a healthcare provider if you develop:

Severe nausea or vomiting
Dehydration
Severe abdominal pain
Pain radiating to the back
Persistent diarrhea
Yellow skin or eyes
Right upper abdominal pain
Symptoms of low blood sugar
Palpitations
Allergic reaction
New depression or suicidal thoughts

Seek urgent medical care for severe abdominal pain, fainting, severe dehydration, trouble breathing, swelling of the face or throat, or symptoms suggesting pancreatitis or gallbladder disease.

External links

Anonymous

Search